<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/69121">
      <dc:title>Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis</dc:title>
      <dc:creator>Zarzuelo Romero, María José</dc:creator>
      <dc:creator>Carrasco Campos, María Isabel</dc:creator>
      <dc:creator>Sánchez Martín, Almudena</dc:creator>
      <dc:creator>Ramírez Tortosa, María Carmen</dc:creator>
      <dc:creator>Jiménez Morales, Alberto</dc:creator>
      <dc:subject>Multiple sclerosis</dc:subject>
      <dc:subject>Natalizumab</dc:subject>
      <dc:subject>Fingolimod</dc:subject>
      <dc:subject>Teriflunomide</dc:subject>
      <dc:subject>Dimethyl fumarate</dc:subject>
      <dc:subject>Alemtuzumab</dc:subject>
      <dc:subject>Cladribine</dc:subject>
      <dc:subject>Siponimod</dc:subject>
      <dc:subject>Ocrelizumab</dc:subject>
      <dc:subject>Response</dc:subject>
      <dc:subject>Polymorphisms</dc:subject>
      <dc:description>The introduction of new therapies for the treatment of multiple sclerosis (MS) is a very recent phenomenon and little is known of their mechanism of action. Moreover, the response is subject to interindividual variability and may be affected by genetic factors, such as polymorphisms in the genes implicated in the pathologic environment, pharmacodynamics, and metabolism of the disease or in the mechanism of action of the medications, influencing the effectiveness of these therapies. This review evaluates the impact of pharmacogenetics on the response to treatment with new therapies in patients diagnosed with MS. The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients. However, there are few existing studies and their samples are small, making it difficult to generalize the role of these genes in treatment with new therapies. Studies with larger sample sizes and longer follow-up are therefore needed to confirm the results of these studies.</dc:description>
      <dc:date>2021-06-11T08:09:50Z</dc:date>
      <dc:date>2021-06-11T08:09:50Z</dc:date>
      <dc:date>2021-04-23</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>Zarzuelo Romero, M.J.; Pérez Ramírez, C.; Carrasco Campos, M.I.; Sánchez Martín, A.; Calleja Hernández, M.Á.; Ramírez Tortosa, M.C.; Jiménez Morales, A. Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis. J. Pers. Med. 2021, 11, 335. [https://doi.org/10.3390/jpm11050335]</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/69121</dc:identifier>
      <dc:identifier>10.3390/jpm11050335</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>